F8 and hemophilia: The ability to eradicate pre-existing neutralizing antibodies to canine FVIII (n = 4) [14] or FIX (n = 1) [24] protein following AAV gene therapy highlights the potential for transgene-specific immune tolerance induction, further supporting the safety of this strategy for outbred dogs with naturally occurring hemophilia.